Effects of an Antagonistic Analog of Growth Hormone-Releasing Hormone on Endometriosis in a Mouse Model and In Vitro
Tóm tắt
Endometriosis is a benign gynecologic disorder causing dysmenorrhea, pelvic pain, and subfertility. Receptors for the growth hormone-releasing hormone (GHRH) were found in endometriotic tissues. Antagonists of GHRH have been used to inhibit the growth of endometriotic endometrial stromal cells. In this study, the GHRH receptor splice variant (SV) 1 was detected in human endometrial tissue samples by Western blots and quantitative reverse transcription polymerase chain reaction (qRT-PCR). The highest messenger RNA (mRNA) and protein levels of SV1 were found in eutopic endometrium from patients with endometriosis compared to ectopic endometriotic tissues and endometrium from normal patients. The highest expression for GHRH mRNA was found by qRT-PCR in ectopic endometriosis lesions. In an in vivo mouse model with human endometrial explants from patients with endometriosis, 10 μg MIA-602 per day resulted in significantly smaller human endometrial xenotransplants after 4 weeks compared to mice treated with vehicle. The endometrial tissues expressed SV1 before and after xenotransplantation. The proliferation of endometrial stromal cells as well as the endometriosis cell lines 12-Z and 49-Z was decreased by exposure to 1 μM MIA-602 after 72 hours. The protein levels of epithelial growth factor receptors in 12-Z and 49-Z cell lines were reduced 48 and 72 hours after the administration of 1 μM MIA-602. MIA-602 decreased the activation of the MAP-kinases ERK-1/2. Our study demonstrates the presence of SV1 receptor as a target for treatment with GHRH antagonist in endometriosis. Endometrial tissues respond to MIA-602 with inhibition of proliferation in vitro and in vivo. The use of MIA-602 could be an effective supplement to the treatment strategies in endometriosis.
Tài liệu tham khảo
Rogers PA, D’Hooghe TM, Fazleabas A, et al. Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci. 2009;16(4):335–346.
Mehedintu C, Plotogea MN, Ionescu S, Antonovici M. Endometriosis still a challenge. J Med Life. 2014;7(3):349–357.
Schally AV, Varga JL, Engel JB. Antagonists of growthhormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab. 2008;4(1):33–43.
Engel JB, Keller G, Schally AV, et al. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. J Clin Endocrinol Metab. 2005;90(6):3614–3621.
Wu HM, Schally AV, Cheng JC, Zarandi M, Varga J, Leung PC. Growth hormone-releasing hormone antagonist induces apoptosis of human endometrial cancer cells through PKCd-mediated activation of p53/p21. Cancer Lett. 2010;298(1):16–25.
Kiaris H, Schally AV, Kalofoutis A. Extrapituitary effects of the growth hormone-releasing hormone. Vitam Horm. 2005;70:1–24.
Fu L, Osuga Y, Yano T, et al. Expression and possible implication of growth hormone-releasing hormone receptor splice variant 1 in endometriosis. Fertil Steril. 2009;92(1):47–53.
Annunziata M, Grande C, Scarlatti F, et al. The growth hormonereleasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line. Fertil Steril. 2010;94(3):841–849.
Kovacs M, Schally AV, Varga JL, Zarandi M. Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists. Curr Med Chem. 2008;15(4):314–321.
Perez R, Schally AV, Popovics P, et al. Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; a preclinical study. Oncoscience. 2014;1(10):665–673.
Koster F, Engel JB, Schally AV, et al. Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. Breast Cancer Res Treat. 2009;116(2):273–279.
Guo J, Schally AV, Zarandi M, Varga J, Leung PC. Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway. Reprod Biol Endocrinol. 2010;8:54.
Banu SK, Lee J, Starzinski-Powitz A, Arosh JA. Gene expression profiles and functional characterization of human immortalized endometriotic epithelial and stromal cells. Fertil Steril. 2008;90(4):972–987.
Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002;30(9): e36.
Pozsgai E, Schally AV, Hocsak E, Zarandi M, Rick F, Bellyei S. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines. Int J Oncol. 2011;39(4):1025–1032.
Pozsgai E, Schally AV, Zarandi M, Varga JL, Vidaurre I, Bellyei S. The effect of GHRH antagonists on human glioblastomas and their mechanism of action. Int J Cancer. 2010;127(10):2313–2322.
Bellyei S, Schally AV, Zarandi M, Varga JL, Vidaurre I, Pozsgai E. GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. Cancer Lett. 2010;293(1):31–40.
Szalontay L, Schally AV, Popovics P, et al. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function. Cell Cycle. 2014;13(17):2790–2797.
Fahrenholtz CD, Rick FG, Garcia MI, et al. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgendependent and castration-resistant human prostate cancer. Proc Natl Acad Sci U S A. 2014;111(3):1084–1089.
Perez R, Schally AV, Vidaurre I, Rincon R, Block NL, Rick FG. Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers. Oncotarget. 2012;3(9):988–997.
Klukovits A, Schally AV, Szalontay L, et al. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers. Cancer. 2012;118(3):670–680.
Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A, Kiaris H. Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormonereleasing hormone receptor. Proc Natl Acad Sci U S A. 2007;104(13):5575–5579.
Wang Q, Wang Y, Fu X, Huang Y. Comparison of expression of growth hormone-releasing hormone and its receptor splice variant 1 in different stages of endometriosis. Int J Fertil Steril. 2013;7(1):33–38.
Du H, Taylor HS. Contribution of bone marrow-derived stem cells to endometrium and endometriosis. Stem Cells. 2007;25(8):2082–2086.
Khorram O, Garthwaite M, Grosen E, Golos T. Human uterine and ovarian expression of growth hormone-releasing hormone messenger RNA in benign and malignant gynecologic conditions. Fertil Steril. 2001;75(1):174–179.
Bruner KL, Matrisian LM, Rodgers WH, Gorstein F, Osteen KG. Suppression of matrix metalloproteinases inhibits establishment of ectopic lesions by human endometrium in nude mice. J Clin Invest. 1997;99(12):2851–2857.
Nisolle M, Casanas-Roux F, Marbaix E, Jadoul P, Donnez J. Transplantation of cultured explants of human endometrium into nude mice. Hum Reprod. 2000;15(3):572–577.
Bergqvist A, Jeppsson S, Kullander S, Ljungberg O. Human uterine endometrium and endometriotic tissue transplanted into nude mice. Morphologic effects of various steroid hormones. Am J Pathol. 1985;121(2):337–341.
Starzinski-Powitz A, Zeitvogel A, Schreiner A, Baumann R. In search of pathogenic mechanisms in endometriosis: the challenge for molecular cell biology. Curr Mol Med. 2001;1(6):655–664.
Aghajanova L, Giudice LC. Molecular evidence for differences in endometrium in severe versus mild endometriosis. Reprod Sci. 2011;18(3):229–251.
Siriwardana G, Bradford A, Coy D, Zeitler P. Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase. Mol Endocrinol. 2006;20(9):2010–2019.
Khan AS, Fiorotto ML, Cummings KK, Pope MA, Brown PA, Draghia-Akli R. Maternal GHRH plasmid administration changes pituitary cell lineage and improves progeny growth of pigs. Am J Physiol Endocrinol Metab. 2003;285(1): E224–E231.
Fiorotto ML, Lopez R, Oliver WT, Khan AS, Draghia-Akli R. Transplacental transfer of a growth hormone-releasing hormone peptide from mother to fetus in the rat. DNA Cell Biol. 2006;25(8):429–437.